Fenouil, T. | Search bioRxiv

bioRxiv2026

Type 1 and type 2 dendritic cell subsets cooperate to maintain intestinal immune tolerance via integrin αvβ8-mediated TGF-β activation

The gastrointestinal tract is a unique immunological environment where the host must balance tolerance to commensal microbes with defense against pathogens. A critical mechanism for maintaining this balance is the peripheral conversion of naive T cells into regulatory T cells (pTregs), a process that depends on the TGF-{beta} cytokine, which is produced in a latent form and must be activated. While the activation of latent TGF-{beta} relies on the membrane-bound v{beta}8 integrin, the precise cellular subset(s) responsible for this essential process have yet to be clearly defined. Conventional dendritic cells (cDCs), which migrate from the intestinal lamina propria to the gut-draining mesenteric lymph nodes (MLN), have long been considered the primary antigen-presenting cells (APCs) responsible for v{beta}8-mediated TGF-{beta} activation and pTreg induction. However, recent studies have challenged this paradigm by highlighting a new family of rare ROR{gamma}t-expressing APCs, able to induce pTreg via v integrins, raising questions about the in vivo role of cDCs in the maintenance of mucosal immune homeostasis. Using a {beta}8 integrin gene reporter mouse model (Itgb8-IRES-tdTomato) combined with single-cell profiling, we comprehensively mapped Itgb8-expressing APCs in the MLN. We show that cDCs, in particular migratory type 1 (cDC1) and type 2 (cDC2), constitute the predominant Itgb8TdTomato+ cells, both in neonatal and adult mice. Through cDC subset-specific {beta}8 knockout models, we demonstrate that both cDC1 and cDC2 are required for optimal pTreg generation. Loss of {beta}8 integrin in either subset led to a partial reduction in pTreg, while combined deletion resulted in profound pTreg loss and spontaneous colitis. Importantly, these effects were independent of ROR{gamma}t APC populations, including ILC3s and Thetis cells. These findings resolve longstanding questions about the identity of key APCs driving pTreg induction in the MLNs. They demonstrate that cDC1 and cDC2 are non-redundant, essential mediators of pTreg induction and intestinal immune tolerance. Although different populations of ROR{gamma}t APCs may contribute in specific contexts, such as early development, infection, or in the prevention of allergic disease, cDCs remain one of the primary guardians of intestinal immune homeostasis in response to microbiota.

immunology↗

bioRxiv2025

Fibrillarin-mediated ribosomal RNA maturation is a novel therapeutic vulnerability in triple-negative breast cancer

Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes to treat due to the lack of effective therapeutic options. Ribosome biogenesis has recently emerged as a promising therapeutic target across various cancers. Despite the current targeting of ribosome biogenesis through RNA polymerase I (RNA Pol I) inhibition, we speculated that other factors essential for ribosome assembly, such as rRNA maturation factors, may also represent therapeutic targets in TNBC. Here, we demonstrate that ribosome biogenesis-related genes are notably overexpressed in TNBC compared to other breast cancer subtypes, highlighting its critical role in TNBC progression. Accordingly, we show that RNA Pol I inhibition exerts potent anti-proliferative effects in pre-clinical models of TNBC, both in vitro and in vivo. However, the DNA-damaging activity of RNA Pol I inhibitors raises safety concerns, highlighting the need for alternative strategies to inhibit ribosome biogenesis. To this end, we show that targeting a downstream rRNA maturation step, specifically pre-rRNA cleavage, by inhibiting the maturation factor Fibrillarin, also inhibits tumor growth in TNBC models. Notably, ribosome biogenesis inhibition, through either RNA Pol I or Fibrillarin targeting, induces cell cycle arrest without triggering significant cell death. These findings establish ribosome biogenesis as a therapeutic vulnerability in TNBC and identify rRNA maturation, and Fibrillarin in particular, as novel targets for potential therapeutic intervention. SignificanceTargeting ribosome biogenesis, through inhibition of either rRNA synthesis or maturation, induces anti-tumoral effects in TNBC, representing a novel therapeutic vulnerability with potential to improve patient outcomes.

cancer biology↗